Navigation Links
Drug-induced liver injury is on the rise
Date:6/26/2013

Bethesda, MD (June 26, 2013) More people are being affected by drug-induced liver injury (DILI) than ever before, according to a new study in Gastroenterology, the official journal of the American Gastroenterological Association. This type of liver injury results from the use of certain prescription and over-the-counter medications, as well as dietary supplements, and is among the more challenging forms of liver disease due to its difficulty to predict, diagnose and manage.

Investigators conducted a population-based study in Iceland uncovering 19.1 cases of drug-induced liver injury per 100,000 inhabitants, per year. These results are significantly higher than the last population-based study of this kind, conducted in France from 1997-2000, which reported 13.9 cases per 100,000 inhabitants, per year.

The most commonly implicated drugs were amoxicillin-clavulante (penicillin used to fight bacteria), azathioprine (an immunosuppressive drug used in organ transplantation and autoimmune diseases) and infliximab (also used to treat autoimmune disease).

"Drug-induced liver injury is not a single, uncommon disease of the general population, but rather a series of rare diseases that occur only in persons who take specific medications," said Einar S. Bjrnsson, lead study author from the department of internal medicine, section of gastroenterology and hepatology, National University Hospital, Reykjavik, Iceland, and faculty of medicine at the University of Iceland. "Our study identified which medications put patients most at risk for developing liver diseases. With this information, physicians can better monitor and manage patients who are prescribed potentially liver-injuring drugs."

The study also showed that drug-induced liver injury was caused by a single prescription medication in 75 percent of cases, by dietary supplements in 16 percent and by multiple agents in 9 percent. Further, the incidence was similar in women and men, but increased with age; not surprising since the need for medication also increases with age.

Jaundice and other symptoms highly suggestive of liver injury, such as itching, nausea, abdominal discomfort and lethargy, were present in the majority of patients. Most patients had a favorable outcome after receiving care.


'/>"/>

Contact: Rachel Steigerwald
media@gastro.org
301-272-1603
American Gastroenterological Association
Source:Eurekalert

Related medicine news :

1. Delivering the best care to the right patient at the right time
2. Dubai's Princess Haya Delivers Stirring Expo 2020 Speech in Paris
3. Author Delivers 25 Life-Building Tools for Recovering Addicts in New Book
4. Freedom Writers Foundation Founder, Erin Gruwell Delivers Keynote Address at American Career College Commencement Ceremony
5. Robert Oliver, Clearwater Professional, Explains Benefits of Medicaid Expansion
6. Novel Drug Delivery Systems Market (NDDS): Formulations (Oral & Injectable) Analysis in Research Report at RnRMarketResearch.com
7. Dr. Rod J. Rohrich Delivers Keynote Address on the Future of Rhinoplasty
8. New Drug Delivery Partnering Terms and Agreements Market Study Report Available at MarketResearchReports.Biz
9. Lauren Sciences independently recognized as a Technology Innovator in Drug Delivery with its V-Smart™ Platform, and selected as a Featured Company, in new report by MCD Group
10. ReNew Life Launches Daily Liver Support™—a Triple-Action, Daily Supplement for Optimal Liver Support
11. Novel Liver Stem Cell Model Could Speed Up Process for Developing New Drugs
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/26/2017)... ... 2017 , ... RawTrition now brings you BioEnergy which is a powder capsule ... , RawTrition is taking nutrients to the next level! The superfoods in ... raw form (unlike the synthetically made options that are on the market). , Founder ...
(Date:4/25/2017)... ... April 25, 2017 , ... ... cream that’s the first in a new class of photodynamic cosmetics (PDC). , ... of skin, visibly reduce outward signs of aging, and minimize the appearance of ...
(Date:4/25/2017)... (PRWEB) , ... April 25, 2017 , ... ... CEOs, CFOs and HR decision-makers are preparing for how his administration could impact ... will provide insight into what changes are most likely to make it through ...
(Date:4/25/2017)... (PRWEB) , ... April 25, 2017 , ... ... targets, they rely on contracted partners to help with process innovation in drug ... combined drug formulation experience along with state-of-the-art analytical equipment in support of their ...
(Date:4/25/2017)... , ... April 25, 2017 , ... ... of predictive analytics to its patient care management module. Using this new feature, ... a patient has been initiated on continuous positive airway pressure (CPAP), oral, or ...
Breaking Medicine News(10 mins):
(Date:4/19/2017)... NEW YORK , April 19, 2017 /PRNewswire/ ... This report on the prostate cancer ... of the global market. Increasing prevalence of prostate ... as innovation in the development of new drugs ... hormone-refractory prostate cancer drug due to lesser side ...
(Date:4/19/2017)... April 19, 2017  Sorrento Therapeutics, Inc. (NASDAQ: ... biopharmaceutical company developing new treatments for cancer and ... of its previously announced underwritten public offering of ... public offering price of $2.00 per share, before ... expenses payable by Sorrento.  The net proceeds to ...
(Date:4/19/2017)... April 19, 2017  Novartis today announced the ... Heart, Lung, and Blood Institute (NHLBI) of the ... of patients with treatment-naïve severe aplastic anemia (SAA) ... with eltrombopag at the initiation of and concurrently ... evaluated three sequential treatment groups, or cohorts. Cohort ...
Breaking Medicine Technology: